at high resolution may optimize insights into emerging trends within cancer care systems.
INTRODUCTION
Treatment uptake and elapsed times along the care path for cancer patients have emerged as potential quality indicators for cancer care delivery [1] [2] [3] . For patients with early-stage non-small-cell lung cancer (nsclc), the care path includes disease detection, surgical resection, and recently, adjuvant chemotherapy 4 .
After curative-intent surgical resection, adjuvant chemotherapy with platinum-based regimens is currently recommended for patients with high-risk early-stage nsclc [5] [6] [7] [8] . In 2004, the calgb (Cancer and Leukemia Group B) 9633 9 and ncic jbr.10 10 trials revealed absolute survival benefits of 5%-10% after adjuvant chemotherapy (compared with observation) for stages ib and ib-ii nsclc respectively. Subsequently, a number of studies in a variety of jurisdictions observed adjuvant chemotherapy uptake rates of only 20%-30% for patients with early-stage nsclc after curative-intent surgery [11] [12] [13] . More recently, longer follow up from calgb 9633 found that the survival benefit associated with adjuvant chemotherapy in stage ib disease was no longer statistically significant 14 . As well, a subset analysis of ncic jbr.10 revealed that the survival benefit in stage ib disease was limited to patients with larger tumours 15 . Adjuvant chemotherapy is therefore not currently routinely recommended for all patients with stage ib disease, and in light of the more recent data, uptake across all disease stages is largely unknown.
We previously examined the patterns of chemotherapy uptake and elapsed times along the care path for a 2005 population-based cohort with early-stage nsclc 11, 16 . Here, we report changes between 2005 and
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All patients who underwent curative-intent surgery for stages i-iii nsclc in the two years of interest were included. Logistic regression and general linear models were used to examine factors associated with chemotherapy uptake patterns and, at various resolutions (low, intermediate, high), elapsed times between all care events in the care path. 2007 in adjuvant chemotherapy uptake and elapsed times along the care path for patients with early-stage nsclc who underwent curative-intent surgery in Nova Scotia, Canada.
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METHODS
The present retrospective study included all patients diagnosed with nsclc in the years 2005 and 2007 who underwent curative-intent surgery for stages i-iii disease. Patients were identified through the Nova Scotia provincial cancer registry and retrospective chart reviews at the two health centres in Nova Scotia in which thoracic surgeries are exclusively performed-the QEII Health Sciences Centre (qeii hsc) in Halifax and the Cape Breton Regional Hospital (cbrh) in Sydney. The study was approved by the ethics review boards at both participating institutions.
Data was abstracted from patient charts and the Oncology Patient Information System (a database maintained by the provincial cancer registry and the regional cancer centres). Included were age at diagnosis, sex, marital status, smoking history, score on the Charlson comorbidity index 17 , distance between residence and cancer centre, disease stage, cancer histopathology, margin status, health centre where definitive surgery occurred, definitive surgery type, postoperative complications, and cohort year. Postal Code Conversion File Plus (PCCF+5F) 18 was used to compute the distance between a patient's residence and the cancer centre and to conduct neighbourhood linkages with 2006 Canadian census data to generate socioeconomic factors such as education level and median household income in the area of the patient residence 16 . Dates of these care events were also abstracted: disease detection ("Detection"), defined as the first abnormal imaging study prompting surgical consultation; first surgical consultation ("Surgery Consultation"); definitive curative-intent surgery ("Surgery"); receipt of referral to medical oncology at one of the two regional cancer centres for consideration of adjuvant systemic therapy ("Medical Oncology Referral"); first medical oncology consultation ("Medical Oncology Consultation"); and initiation of the first cycle of adjuvant chemotherapy ("Adjuvant Chemotherapy").
The proportions of patients referred to medical oncology after curative-intent surgery (that is, "Referral") and the proportions of patients treated with adjuvant chemotherapy after referral ("Treatment") were examined. As well, the proportions of patients treated with adjuvant chemotherapy among all those undergoing curative-intent surgery ("Uptake") were computed to conform with other published studies that reported only overall uptake, but not referral and treatment patterns separately. Univariate and multivariate logistic regressions were used to identify factors influencing Referral, Treatment, and Uptake patterns. Only factors with a univariate probability of nonrandom association less than 0.3 and the cohort year (fixed-effect) were entered into the multivariate analyses. The Referral analysis included all disease stages; the Treatment and Uptake analyses were limited to stages ib-iii because adjuvant chemotherapy is not routinely recommended for patients with stage ia disease. The outcome variables were coded dichotomously (0 or 1): that is, referred or non-referred for the Referral analysis, and treated or not treated for the Treatment and Uptake analyses. Only patients with data available for all variables were included in the multivariate analysis. Tests of interaction between cohort year and other variables were also conducted.
Elapsed times between care events were examined at three levels of care interval resolution 16 : low (Detection to Adjuvant Chemotherapy), intermediate (Detection to Surgery and Surgery to Adjuvant Chemotherapy), and high (Detection to Surgery Consultation, Surgery Consultation to Surgery, Surgery to Medical Oncology Referral, Medical Oncology Referral to Medical Oncology Consultation, and Medical Oncology Consultation to Adjuvant Chemotherapy). All care intervals were calculated in calendar days, and only patients who experienced both events defining an interval were included in the analysis of that interval. Days were logarithmically transformed (in days + 1) to better meet the assumption of normality. A general linear model was used to identify the primary cofactors influencing elapsed times at the three levels of care interval resolution. Geometric mean wait times and their 95% confidence intervals (cis) were estimated after adjusting for all cofactors that significantly influenced wait times. Data quality control and analyses were performed using the SAS software application (version 9.1: SAS Institute, Cary, NC, U.S.A.). Figure 2 shows patterns of Referral, Treatment, and overall Uptake according to cohort year, and 
DISCUSSION
The significant changes in chemotherapy Uptake (27% in 2005 vs. 16% in 2007) and in elapsed times observed in our study arose over a relatively short period and suggest that frequent monitoring of care indicators will be required to better capture emerging or evolving trends in care patterns. A number of other studies have also reported significant changes over time in chemotherapy Uptake for patients with early-stage nsclc 12,13,19 and also in elapsed times for patients with early-stage breast cancer 20 . More importantly, the more detailed analysis of overall treatment Uptake (that is, the analysis of referral and treatment patterns separately) and the elapsed-times analyses based on high-resolution care intervals (compared with intervals used in other reports) in the present study were more informative in understanding changes in care patterns [21] [22] [23] . The analysis of overall Uptake identified a number of factors associated with higher chemotherapy use, including younger age, less comorbidity, higher disease stage, cbrh treatment centre, and moreaggressive surgery. However, the detailed analyses of Referral and Treatment further highlighted factors that could have potentially influenced decisions by surgical and medical oncologists. Patients with higher-stage disease (ii/iii vs. ib vs. ia) and those who underwent more-aggressive surgery (pneumonectomy vs. lobectomy) were more likely to be referred by surgeons for consideration of adjuvant chemotherapy. In contrast, patients less than 65 years of age and those without comorbidities were more likely to undergo chemotherapy after their medical oncology consultation. A greater proportion of Referrals and Treatments were also both observed at the cbrh centre than at the qeii hsc, perhaps reflecting different practice patterns between the smaller communitybased centre (cbrh) and the larger tertiary-care centre (qeii hsc).
The elapsed-times analyses based on highresolution care intervals also revealed wait-time patterns that were undetected at low-or intermediate-resolution intervals. In our study, differences in elapsed times between the 2005 and 2007 cohorts at low-or intermediate-resolution intervals were nonsignificant, but patients in 2007 experienced shorter elapsed times between Surgery and Medical Oncology Referral and longer elapsed times between Medical Oncology Consultation and Adjuvant Chemotherapy than did patients in 2005. The former decrease in elapsed time could be the result of a more efficient process of identifying patients who would potentially benefit from Medical Oncology Consultation after Surgery, and the latter increase in elapsed time might indicate limitations in system capacity at the level of Medical OncologyConsultation despite fewer referrals for adjuvant nsclc chemotherapy. Overall, a median elapsed time of approximately 7.5 weeks (53 days) was observed between Surgery and Adjuvant Chemotherapy in our study, which is generally consistent with the 6-to 8-week post-surgery timeline criterion used for enrolment in clinical trials that examined adjuvant chemotherapy in lung cancer [7] [8] [9] [10] 16 . The foregoing observations highlight the complexity of the balance between care demand and system capacity in health care systems and also the balance between wait times for one disease site apart from all other competing ones. Nevertheless, elapsed-time monitoring at high-resolution intervals could provide opportunities for relevant intervention to maintain wait times within acceptable benchmarks.
Disease stage was an important predictor of Referral and overall Uptake, but not of Treatment. Overall, compared with patients having stage ib disease, those with stage ii /iii disease were more likely to be referred (79% vs. 39%; or: 4.9; 95% ci: 2.1 to 11.7; p < 0.001), although disease stage was not an independent predictor of adjuvant chemotherapy administration after referral. That observation perhaps suggests that surgeons selectively refer patients with stage ib disease who are more likely to be recommended for, or to accept, adjuvant chemotherapy. Interestingly, in 2007 compared with 2005, patients with stage ib disease were less likely to be referred to medical oncology, and those referred at qeii hsc were less likely to receive adjuvant chemotherapy after referral. The decline in stage ib referrals was expected given the recently demonstrated lack of survival benefit for adjuvant chemotherapy in stage ib disease with small tumour size 8, 14, 24, 25 . A recent Canadian study from Alberta similarly observed a significant decline in adjuvant chemotherapy uptake for stage i b lung cancer in 2006 compared with 2005 or 2004 13 . However, the overall decline in chemotherapy administration observed in our study in 2007 at qeii hsc was somewhat surprising. It could, perhaps, ref lect an overall declining enthusiasm for platinum-based chemotherapy, given the relatively modest associated survival benefit and the potential residual peripheral neuropathy. Cancer centre was also an important predictor of treatment Uptake and patterns of elapsed time. Overall, referral to medical oncology and treatment with adjuvant chemotherapy were more likely in patients treated at cbrh than in those treated at the qeii hsc, and the patients at cbrh also experienced shorter waits along the care path at a number of care intervals, including disease Detection to Surgical Consultation, Surgical Consultation to Surgery, and Medical Oncology Referral to Medical Oncology Consultation. Moreover, the lower Treatment and overall Uptake observed in 2007 compared with 2005 were observed only at qeii hsc and not at cbrh. Those observations may partly reflect differences between the smaller community-based centre (cbrh) and the larger tertiary-care centre (qeii hsc) in the conduct or effect of multidisciplinary team meetings, in system capacities, in centre-specific guidelines, or in patient demographic factors. More importantly, they also illustrate differences in practice patterns across health care centres and the caution that is required in generalizing observations from singlecentre studies.
Our study has limitations. We could not examine all factors potentially influencing treatment Uptake or elapsed times, such as patient preference and missed or cancelled appointments, because the relevant data were not available. We did not perform a comprehensive second-order (between-cofactor) analysis of interactions for all factors because of the study's relatively small sample size. We also did not examine the potential effect of either chemotherapy Uptake or elapsed times on survival outcomes or quality of life, and therefore the clinical impact of our observations on patient outcomes is unknown. In other studies, Mohammed et al. 26 documented nsclc disease progression while the patient awaited treatment, but Diaconescu et al. 27 found no correlation between treatment delays and inferior survival. Finally, and although our study is population-based, the results may not be generalizable to all other jurisdictions. The relatively lower uptake of chemotherapy in our study could be a result of the proportion (about 70%) of patients with stage i disease in our population-based cohort, which is large compared with that in populations from individual tertiary-care centres that primarily see patients at more advanced disease stages. Massard et al. 28 and Kassam et al. 29 reported overall chemotherapy uptake rates of 40% and 46% for patient cohorts involving 53% and 67% stage i disease respectively.
CONCLUSIONS
This population-based study of chemotherapy uptake and wait times in early-stage nsclc suggests that frequent monitoring of care patterns at high resolution may optimize insights into emerging trends within cancer care systems. 
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